Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

MYC

9 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Bioinfo & AI

GiGCN: a network-based framework for uncovering synthetic lethal and viable genetic interactions

Wang Q, Yang F, Fu M, et al.

Briefings in bioinformatics

This study introduces GiGCN, a novel graph convolutional network framework designed for the joint identification of synthetic lethal (SL) and synthetic viable (SV) genetic interactions. By integrating verified genetic interactions and gene semantic similarities, GiGCN separately models distinct functional dimensions within gene networks. This approach significantly enhances prediction accuracy compared to existing methods, achieving AUC and AUPRC values of 0.978 and 0.944, respectively. Further analyses revealed SL interactions centered on the MYC oncogene and SV interactions linked to autophagy, providing crucial mechanistic insights. The ultimate goal is to facilitate the discovery of actionable therapeutic targets for cancer and other human diseases.

Clinical · Molecular biology

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Yu HA, Tang KH, Markovets A, et al.

Clinical cancer research

The Phase II ORCHARD study investigated resistance mechanisms to first-line osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Utilizing next-generation sequencing (NGS) on both tissue and plasma samples, the study characterized the molecular profile of tumors after progression. Resistance alterations were detected in 87% of samples, often multiple, involving genes such as TP53, MDM2/4, PI3K, SOX2, and MYC. These findings highlight the heterogeneity of resistance and provide a rationale for exploring combination therapies to improve patient outcomes.

Clinical · Molecular biology · Bioinfo & AI

Pleomorphic Liposarcoma: Comprehensive Genomic Analysis of 39 Cases With Comparison to Other Genomically Complex Sarcomas

Yakoub MA, Saoud C, Kim D, et al.

Genes, chromosomes & cancer

This study conducted comprehensive genomic profiling on 39 cases of pleomorphic liposarcoma (PLPS) to characterize its molecular landscape and compare it with other complex sarcomas like UPS and MFS. Analyses revealed that TP53 (87%) and RB1 (51%) alterations are the most frequent in PLPS, and significantly more common than in UPS and MFS. MYC amplification was associated with significantly shorter overall survival, suggesting a prognostic role. Furthermore, correlations were established between gene alterations and morphological features, including CYSLTR2 alterations in cases with predominant pleomorphic lipoblasts. These findings highlight the molecular distinctiveness of PLPS and provide insights for future diagnostic and therapeutic strategies.

Clinical · Molecular biology

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer

Xie J, Wang S, Liu J, et al.

Apoptosis

This study investigates the interaction between mutated KRAS and AGO2 in colorectal cancer (CRC), a mechanism that impairs AGO2 function and promotes tumor progression. Researchers developed peptide-gold nanoparticles (Au-pep) to specifically disrupt this interaction, which restored microRNA expression, particularly let-7c-5p. This restoration led to the downregulation of key oncogenic drivers such as KRAS, c-Myc, and Bcl2, suppressing the growth of KRAS-mutated CRC cells and inducing apoptosis. Furthermore, this approach sensitized cells to existing treatments, including 5-fluorouracil and immunotherapy, by regulating ABCC5 and PD-L1.

Clinical · Molecular biology

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study

Hartley HE, Fong FC, Gabriel AS, et al.

JCO precision oncology

This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.

Clinical · Molecular biology

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Dymun A, Jeng MY, Elkrief A, et al.

Science translational medicine

This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.

Clinical

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial

Xu PP, Song YQ, Shen JZ, et al.

JAMA

A randomized, placebo-controlled phase 3 clinical trial investigated the addition of tucidinostat, a histone deacetylase inhibitor, to standard R-CHOP in patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma (DEL). The study demonstrated a significant improvement in event-free survival (EFS) in the tucidinostat group, with a 28% lower risk of events and a two-year EFS rate of 60.3% versus 50.5% for the placebo group. The complete response rate was also higher (73.0% vs 61.8%). Although increased toxicity was observed with tucidinostat, it was generally manageable.

Clinical · Molecular biology

The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors

Braat J, Trichy NS, Holic LJ, et al.

Human pathology

This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.